cancer treatment

J&J says drug combo cut myeloma death risk by 62% in trial

Johnson & Johnson on Wednesday announced that the phase 3 MonumenTAL-6 trial met its primary endpoint, with the combination of Tecvayli (teclistamab) and Talvey (talquetamab) reducing the risk of disease progression or death by 89% and the risk of death…